Lowe oculocerebrorenal syndrome (OCRL) (MIM 309000) is a rare X-linked multisystem disorder characterized by congenital cataracts, muscular hypotonia, areflexia, mental retardation, maladaptive behavior, renal tubular dysfunction, vitamin-Dresistant rickets, and scoliosis. The underlying gene OCRL1 is located on chromosome Xq25-q26 and contains 24 exons. It encodes a 105-kDa phosphatidylinositol 4,5-bisphosphate (PtdIns[4,5]P 2 ) 5-phosphatase that is localized to the Golgi complex. To confirm the clinical diagnosis and to assess the carrier state of female relatives for genetic counseling we examined 6 independent patients and their families (a total of 23 individuals) using an improved mutation screening strategy for the OCRL1 gene by sequencing of large PCR amplicons. Four novel and two known mutations were identified: three premature terminations caused by either frameshift mutations (1899insT in exon 17 and 2104 -2105delGT in exon 18) or a nonsense mutation (1399C > T in exon 12), two missense mutations (1676G > A and 1754C > T in exon 15), and a 6-bp deletion (1609 -1614delAAGTAT in exon 14 ). An ophthalmological examination was performed in all patients and 14 female relatives. All genotypically proven carrier females showed characteristic lenticular opacities, while all proven noncarriers were lacking this phenotypic finding. The results confirm that ophthalmological evaluation is an apparently reliable first-line method to ascertain the carrier state in Lowe oculocerebrorenal syndrome. The high expressivity of lenticular symptoms in OCRL1 gene carriers is consistent with the hypothesis that (PtdIns[4,5]P 2 ) 5-phosphatase activity has low functional reserve capacity for maintaining a balanced homeostasis of lenticular metabolism.
In 1952 three patients with abnormalities of renal function, bone disease, mental retardation, and congenital glaucoma were first described (1) . The hallmark of Lowe oculocerebrorenal syndrome (OCRL) is the presence of prenatally developed cataracts. Fanconi's syndrome of the renal tubule with tubular acidosis, bicarbonaturia, phosphaturia with vitamin-D-resistant rickets, hypercalciuria, proteinuria, generalized aminoaciduria, polyuria, and carnitine wasting is the second major feature, which is variable both in age of onset and in severity. In their second or third decade, however, OCRL patients eventually succumb to renal failure or infection. The third prominently involved organ in this condition is the central and peripheral nervous system with two cardinal features: neonatal muscular hypotonia and areflexia by 1 year of age. Psychomotor retardation, seizures, and stereotypic behavioral abnormalities are also common features. A variety of additional organ systems may be involved.
The basic defect in OCRL is still not completely understood. The chromosomal location of the OCRL gene, Xq25-q26, was determined both by finding balanced X;autosome translocations with a breakpoint in band Xq25-q26 in two unrelated female patients (2, 3) and by linkage analysis with RLFP in families with multiple affected individuals (4 -7) . The underlying gene, OCRL1, was isolated by positional cloning, and the transcript was demonstrated to be absent or abnormally sized in OCRL patients (8) . The gene consists of 24 exons spanning about 58 kb (9) . The open reading frame encodes a protein with 71% similarity to human inositol polyphosphate 5-phosphatase suggesting that OCRL may be an inborn error of inositol phosphate metabolism (8) . It is hypothesized that the deficiency of a Golgi (PtdIns [4, 5] P 2 ) phosphatase results in dysregulation of Golgi vesicular transport causing cataracts and abnormal neurological and renal function (10) . At least 30 distinct mutations in 34 independent patients have been found so far (11) (12) (13) (14) (15) . Interestingly, mutations are clustered in only 13 of the 24 exons with missense mutations being restricted to exons 12 to 15 in residues that are highly conserved among different phosphatidylinositol 5-phosphatases (16) . For genetic counseling it is critical to ascertain the carrier state as early as possible, since no specific therapy is available for this condition. If direct mutation analysis is not possible, lens examination to identify opacities has been advocated for this purpose. The reliability of this method alone, however, cannot be verified with certainty so far.
In this study, by sequencing large amplicons, we established an improved approach for mutation screening which is suitable for facilitating and speeding up the identification of OCRL1 homozygotes and hemizygotes. Six independent patients and their families (a total of 23 individuals) were investigated by DNA sequencing. We identified four hitherto unknown and two known mutations. Since female carriers are usually asymptomatic, but may show opacities on slit-lamp examination (17) , an ophthalmological examination was performed in all patients and 14 female relatives to correlate OCRL genotypes to ophthalmological phenotypes and to assess the sensitivity of an eye examination in the detection of carriers for the purpose of genetic counseling.
SUBJECTS AND METHODS

Patients and Relatives
Peripheral blood leukocytes were obtained from six independent affected male individuals with a clinical diagnosis of OCRL based on the characteristic hallmarks of congenital cataracts, psychomotor retardation, and renal tubular dysfunction. Informed consent for genetic analysis of each patient was obtained from the parents. Blood samples were taken from 17 postpubertal female relatives. The females were tested only for the mutation found in the proband. An ophthalmological examination was carried out on all patients and on 14 of the female family members who were obligate carriers or could be carriers of a OCRL1 mutation based on the position in the pedigree (six mothers, four sisters of patients, two maternal aunts, and two daughters of one maternal aunt).
PCR Fragment Amplification
A total of 200 -400 ng of genomic DNA prepared from peripheral blood leukocytes was used as a template for the PCR amplification of the 23 coding OCRL1 exons. In order to produce large fragments containing several exons we used the Expand Long Template system (Boehringer Mannheim) with 350 M of each dNTP, 2.5 U of the DNA polymerase mix, 10 pmol of each primer, and the following cycling conditions: 1ϫ 94°C for 2 min, 35ϫ 94°C for 30 s, 53°C for 30 s, 68°C for 4 min, and 1ϫ 68°C for 3 min. Exon 2 was amplified using Taq DNA polymerase (Boehringer Mannheim) under standard conditions and the following cycling program: 1ϫ 94°C for 5 min, 35ϫ 94°C for 1 min, 58°C for 1 min, 72°C for 30 s, and 1ϫ 72°C for 2 min.
Sequencing of PCR Products
The PCR products were column-purified using the QIAquick PCR purification kit (Qiagen). The sequencing reactions were performed in a final volume of 5 l containing 2 l dRhodamine Terminator Ready Reaction mix, 10 pmol primer, and 100 -200 ng purified PCR product. Cycle sequencing conditions were as follows: 27ϫ 94°C for 15 s, 53°C for 15 s, 60°C for 4 min. Samples were then precipitated and separated on an Applied Biosystems PRISM 377 DNA sequencer. ABI PRISM Sequence Navigator software was used for analysis of the sequences.
Ophthalmological Investigation
An eye examination in female carriers and noncarriers including visual acuity and funduscopy was done by a single observer (GR) with the exception of the mother of patient ZS-203 (Fig. 3) . The ophthalmologist was masked to the pedigree status and to the mutational status of the individuals. Measurement of visual acuity was not possible in the affected males due to mental retardation and reduced compliance. To perform slit-lamp examination (Zeiss, Oberkochen) pupils were dilated with 5% tropicamide (Mydriaticum Stulln) and 5% phenylephrine hy-drochloride (Neosynephrin-POS), two applications of each over the course of 20 min. To quantify the lens changes the opacity score according to Brown and Gardner was used (17) .
In addition, the opacities were characterized with regard to their location (typically clustered in radial bands or wedges in the peripheral lenticular cortex), their distribution (characteristically like the hours on a clock face with some positions missing), their size and shape (small and irregularly shaped), and their quality (off-white in color, nonrefractile in texture) (21) .
RESULTS
Mutation Analysis of the OCRL1 Gene
A new strategy for mutation detection was chosen by amplifying the 23 coding exons of the 58-kb gene into six fragments. Exon sequences were determined by cycle sequencing using amplification primers and internal intron primers. Details of the strategy for amplification and sequencing are summarized in Fig. 1 . Primer sequences-as largely described by Nussbaum et al. (9)-used for production of PCR amplicons containing one or several OCRL1 exons and fragment lengths are listed in Table 1 . We identified six mutations consisting of four novel and two known mutations. By analysis of 17 female relatives we found 6 carriers and 11 noncarriers indicating four de novo mutations. The six mutations are either located in one of the conserved blocks or result in an immediate or successive termination codon (see Fig.  2B ). Pedigrees of the families summarizing index patients, carriers, noncarriers, and individuals who were investigated by slit-lamp examination are shown in Fig. 3 . Two frameshift mutations were identified resulting in premature terminations of the ocrl1 protein: patient HN-8864 showed a 2-bp deletion in exon 18, causing a nucleotide change of 2104 -2105delGT and a successive termination (D634X); patient JT-3890 had a T insertion in exon 17 resulting in a nucleotide change at position 1899 and in an immediate termination codon (E558X). Patient ZS-203 exhibited a nonsense mutation in exon 12, a C-to-T transition at base 1399, leading to a termination codon (Q391X). Two additional patients and 5 female carriers were found to have missense mutations in exon 15: patient ZL-2289, his sister, his mother, 2 sisters of his mother, and the maternal grandmother showed a G-to-A transition at base 1676 of the gene, resulting in an amino acid substitution of arginine to glutamine at position 483 (R483Q); patient SR-3377 had a C-to-T transition at base 1754, changing proline at position 509 to leucine (P509L). Patient MD-170 and his mother carried a 6-bp deletion in exon 14 (1609 -1614-delAAGTAT) leading to a loss of a lysine and a tyrosine residue at the positions 478 -479 (delKY478 -479). Sequences of the OCRL1 regions including the four novel mutations are shown in Fig. 4 . Involved exon, mutation type, nucleotide change, and predicted effect on protein level of all six identified mutations in 23 investigated individuals are summarized in Table 2 .
Ophthalmological and Clinical Findings
The pedigrees of the families with Lowe oculocerebrorenal syndrome including 6 index patients, 6 carriers, and 11 noncarriers are presented in Fig. 3 . All 6 index patients, their mothers, 4 sisters of the patients, 2 maternal aunts, and 2 daughters of a maternal aunt (a total of 20 individuals) were investigated by slit-lamp examination. The ophthalmological findings are summarized in Table 3 .
All genotypically proven carriers presented with significant ophthalmological changes: The mother of patient ZL-2289 (II:4) showed dense opacities in a radial wedge-like pattern with flake-like opacities and clusters of opaque tiny spots (Fig. 5A) ; her second daughter (III:13) demonstrated dense equatorial and anterior cortical clusters of opacities in an outlined radial wedge pattern according to a score of 2ϩ in her right eye and 3ϩ in her left eye (Figs. 5B and 5C); the mother of patient MD-170 (II:2) was pseudophakic after surgical removal of cataracts. The written and photographic records on her lenticular opacities before bilateral cataract extraction are compatible with her carrier status. Three additional obligate carriers (family of patient ZL-2289) were not available for an eye examination.
Ten of eleven genotypically proven noncarriers showed either no lenticular changes or few tiny nonspecific cortical dots and were scored normal. The biomicroscopic examination of the maternal aunt of patient MD-170 (II:3) demonstrated tiny cortical opacities distributed in a radial pattern near the equator of the lens with a scoring of 2ϩ in her right eye and ϩ in her left eye, while clusters of small, multiple off-white opacities were not present (Fig.  5D ).
The affected males were aphakic after having obtained cataract surgery earlier. Patient ZL-2289 is a 13-year-old boy who was diagnosed late at the age of 6 years. He is mentally and developmentally severely retarded. Patient SR-3377 is 21 years old and was diagnosed at the age of 2 months. His mental and developmental status is moderately retarded. Patient JT-3890 is a 7-year-old boy who was diagnosed at the age of 7 months. The additional diagnosis of congenital adrenal hyperplasia with salt wasting was made and confirmed genetically. He is mentally and developmentally severely retarded. Patient HN-8864 is a 3-year-old boy who was diagnosed early at the age of 2 weeks. He is fairly well developed. Patient MD-170 is 28 years old and was diagnosed at the age of 7 months. At 11 years of age he developed seizures and is moderately retarded.
Patient ZS-203 is 17 years old. He was diagnosed at the age of 4 weeks and his case was published in a short case report (18) . The patient developed seizures and is moderately retarded.
DISCUSSION
Lowe oculocerebrorenal syndrome is the only known inherited disorder in humans based on a disturbance in the inositol phosphate signaling pathway. By elucidation of a number of different mutations it was demonstrated that this clinical entity is caused by mutations in the OCRL1 gene encoding a (PtdIns [4, 5] (1754C Ͼ T) are located in exon 15. The G Ͼ A mutation was recently described (13) , whereas the C Ͼ T mutation was newly discovered.
Three additional new mutations were found: two frameshift mutations with premature terminations in patient HN-8864 (2-bp deletion in exon 18) and in patient JT-3890 (1-bp insertion in exon 17) and a 6-bp deletion in exon 14 in patient MD-170 being in agreement with the observation that mutations are limited to only 13 of the 24 exons of the OCRL1 gene:
FIG. 3.
Pedigrees of six families with Lowe oculocerebrorenal syndrome including 6 female carriers and 11 female noncarriers. Mutational analysis and an ophthalmological examination were carried out on all patients and on female family members who were obligate carriers or could be carriers of a OCRL1 mutation based on the position in the pedigree to correlate OCRL genotypes to ophthalmological phenotypes. All carriers were clearly identified both by mutation analysis and by lens examination. Two maternal aunts and the grandmother of patient ZL-2289 were not available for ophthalmological investigation. (14) .
It is striking that two reported mutations (15) (missense C1738G in exon 15 leading to R483G and nonsense G1900T in exon 17 leading to E558X) result in changes at the same locations on the protein level as found in our distinct mutations (missense 1676G Ͼ A in exon 15 and 1-bp insertion in exon 17). While in exon 15 the effect is different (R483Q), both mutations in exon 17 lead to the identical stop codon E558X. Although the sample number is too small to be statistically significant, it is an interesting observation that we identified four de novo mutations in six index patients, which exceeded the expectation that one-third of severe X-linked disorders in each generation originate from new mutations (19) .
Based on the known phenotypic heterogeneity in OCRL patients, it would be tempting to correlate distinct mutations to different clinical phenotypes. This approach, however, may not be successful, since neither the exact function of the ocrl1 protein nor the relevance of its tissue distribution in the single patient are clear and additional factors may become operative. The observation of a different clinical phenotype in two unrelated patients with the identical nonsense mutation supports this hypothesis (11). Nevertheless, we were able to confirm that the phenotype of severe mental and developmental retardation (13) may be related to a specific missense mutation (1676G Ͼ A in exon 15). Our second severely retarded patient, JT-3890, had a frameshift mutation leading to an immediate termination codon, whereas patient MD-170 has a moderate and the patients SR-3377 and HN-8864 have a mild clinical course. In a Japanese patient, who appeared to have a moderate clinical course (14) , the nonsense mutation identical to the one in our patient ZS-203 was found with a similar clinical phenotype (18) . Surprisingly, in patient JT-3890 the additional diagnosis of congenital adrenal hyperplasia with salt wasting was made (CA21H). Mutation scanning in the CYP21 gene revealed a homozygous splice site mutation in intron 2 (656A/C Ͼ G) (20) . Since no specific therapy can be offered for OCRL patients, the early identification of the female carrier status is of great value. Among the different methods of carrier detection the assay of (PtdIns[4,5]P 2 ) 5-phosphatase acitivity has been shown not to be an accurate tool presumably due to random X-inactivation (12) . Cataracts have been found in nearly all patients, while lens opacities in female relatives of affected patients have been considered indicative of the heterozygote status. The occurence of age-dependent opacities in the general population and the difficulty in clearly separating obligate heterozygotes from this group have been major drawbacks in using eye examinations for carrier detection.
The present study shows that mutation analysis can both clearly confirm the clinical diagnosis and detect female heterozygotes. Adequate ophthalmological investigations may serve as a first-line method for predicting OCRL carrier status. In order to assess the reliability of ophthalmological findings for carrier prediction, all eye examinations of the female relatives were carried out without prior knowledge of both the pedigree and the genetic information. Three of six genetically proven obligate carriers were clearly identified both by mutation analysis and by lens examination (2 maternal aunts and the maternal grandmother of patient ZL-2289 were not available for the ophthalmological exam). As in a recently published study on the carrier state of 31 female relatives in three families (21), we could confirm that the sensitivity of slit-lamp examination for OCRL1 carrier assessment is 100% in postpubertal females. Ten women at risk for carrying the OCRL1 gene were identified as noncarriers by mutation analysis. All but 1, the maternal aunt of patient MD-170, had clearly negative eye exams in agreement with negative genetic results. But even in this individual neither the number of opacities (opacity score ϩ and 2ϩ) nor the distribution (no clustering) reflected lenticular changes typically observed in OCRL heterozygotes. In addition, the noncarrier status was verified by mutational analysis of a second blood sample to rule out any potential error.
The high expressivity of lenticular symptoms in OCRL1 gene carriers is consistent with the hypothesis that (PtdIns[4,5]P 2 ) 5-phosphatase activity has low functional reserve capacity for maintaining a balanced homeostasis of lenticular metabolism. Apparently opacities in obligate heterozygotes may develop regardless of the variable proportion of cells in the lens with an inactivated normal OCRL1 allele.
In our study both genetic and opthalmological analyses proved to be an accurate tool for carrier determination (5, 7) . Direct mutation analysis is certainly the method of choice in families in which the mutation is known. The first germline mosaicism, however, was recently detected in one family (15) making the evaluation of the recurrence risk difficult.
Our results demonstrate that the absence of lenticular opacities in at-risk individuals has a high reliability for predicting noncarrier status. The positive predictive values in the presence of lenticular opacities are obviously dependent on the availability of a highly skilled and experienced ophthalmological investigation (17) . Positive prediction may also be diluted in a few instances, where borderline lenticular changes prevent a secure distinction of a female heterozygote from a control with age-dependent opacities. Nonetheless, in situations where the mutation of the index patient is unknown, an ophthalmological examination may help unless dependable sequencing techniques are available. The sensitive dRhodamine dye terminator sequencing method used in this study has also been applied with success in our group for heterozygote detection in X-linked adrenoleukodystrophy, even in cases where the mutation in the index patient was unknown (22) .
The efficient approach to sequence large amplicons of the OCRL1 gene described in this paper may further facilitate rapid mutation screening, heterozygote detection, and prenatal diagnosis in Lowe oculocerebrorenal syndrome. Ophthalmological examination remains an important complementary tool for detecting carrier females for adequate genetic counseling.
